GLP-1 side effects and weight loss claims fact-checked

What's this video probably claiming?

Without a transcript, we're working from context here. @amyvisme is posting in the GLP-1 space on TikTok, which means the video is almost certainly covering personal experience with semaglutide or tirzepatide, side effect management, or weight loss results. The GLP-1 content ecosystem on TikTok in 2024-2025 skews heavily toward before-and-after testimonials, tips for managing nausea, speculation about "food noise" reduction, and comparisons between Ozempic and Wegovy or Mounjaro and Zepbound. Creators in this space frequently blend genuine patient experience with oversimplified physiology. The absence of hashtags here is worth noting. That could mean this is a more personal, diary-style post rather than an intentional reach play, which sometimes makes the claims more credible and sometimes more anecdotal and uncontextualized. We'll update this fully once we have the transcript.

What does the science actually show?

GLP-1 receptor agonists have some of the most strong weight loss data in modern pharmacology. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced mean body weight reduction of 20.9% over 72 weeks in adults with obesity. Semaglutide 2.4mg weekly showed 14.9% mean weight loss in STEP 1 (Wilding et al., 2021, NEJM). These are not trivial numbers. However, those outcomes come with caveats that TikTok rarely mentions. Roughly 40-50% of participants in these trials experienced nausea, 25-30% vomiting, and 20-30% diarrhea. Discontinuation rates due to adverse events were around 4-7%. The physiological mechanism involves GI motility slowing, central appetite suppression via hypothalamic GLP-1 receptors, and incretin effects on insulin secretion. The "food noise" framing popular on social media has some neurobiological plausibility but no clean clinical definition in the literature yet.

Where does the social media noise diverge from clinical reality?

The biggest distortion in GLP-1 TikTok content is the implicit suggestion that these medications work the same way for everyone and that dramatic results are the norm rather than the upper end of the distribution. In STEP 1, roughly 30% of participants lost less than 10% of body weight on semaglutide 2.4mg. That is not a failure, but it does not match the transformational narratives dominating the feed. Second, the rebound data is consistently underreported. Wilding et al., 2022 (Diabetes, Obesity and Metabolism) showed that one year after stopping semaglutide, participants regained approximately two-thirds of their lost weight. Creators who document their weight loss journey rarely stick around to document that part. Third, the off-label use of lower-dose Ozempic (approved for type 2 diabetes) for weight loss instead of Wegovy raises real prescribing and dosing questions that a 60-second video cannot responsibly address.

What should you actually know?

If you are watching GLP-1 content on TikTok and considering these medications, there are a few things worth anchoring to. First, semaglutide and tirzepatide are legitimate, well-studied drugs with meaningful clinical trial data behind them. The hype, for once, is not entirely disconnected from reality. Second, they are not equivalent to each other. Tirzepatide is a dual GIP/GLP-1 agonist and the head-to-head data (SURMOUNT-5, presented at ADA 2025) suggests greater weight loss than semaglutide in most patients. Third, compounded versions of these drugs differ from brand-name products in ways that matter, and claims of equivalency are not supported by available evidence. Fourth, these are long-term medications for a chronic condition. Anyone framing them as a short-term fix is not giving you the full picture. Talk to a licensed prescriber who can review your full health history before starting.